{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:39:20Z","timestamp":1793047160507,"version":"4.5.0"},"reference-count":226,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006537","name":"Vanderbilt University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH124671"],"award-info":[{"award-number":["MH124671"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH065215"],"award-info":[{"award-number":["MH065215"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH136164"],"award-info":[{"award-number":["MH136164"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS143120"],"award-info":[{"award-number":["NS143120"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS031373"],"award-info":[{"award-number":["NS031373"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS132060"],"award-info":[{"award-number":["NS132060"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.schres.2026.06.012","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:29:51Z","timestamp":1781670591000},"page":"236-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia"],"prefix":"10.1016","volume":"295","author":[{"given":"Niki M.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Holter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Niswender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb0005","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.neuron.2018.09.029","article-title":"Somatostatin interneurons facilitate hippocampal-prefrontal synchrony and prefrontal spatial encoding","volume":"100","author":"Abbas","year":"2018","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/archpsyc.1995.03950170015003","article-title":"Symptoms of schizophrenia: methods, meanings, and mechanisms","volume":"52","author":"Andreasen","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1523\/JNEUROSCI.2310-14.2015","article-title":"Early-course unmedicated schizophrenia patients exhibit elevated prefrontal connectivity associated with longitudinal change","volume":"35","author":"Anticevic","year":"2015","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.schres.2026.06.012_bb0020","first-page":"860","article-title":"Using MoCA-Thai to evaluate cognitive impairment in patients with schizophrenia","volume":"96","author":"Arunpongpaisal","year":"2013","journal-title":"J. Med. Assoc. Thailand"},{"issue":"11","key":"10.1016\/j.schres.2026.06.012_bb0025","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/s41386-018-0059-z","article-title":"Cortico-thalamic hypo- and hyperconnectivity extend consistently to basal ganglia in schizophrenia","volume":"43","author":"Avram","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"21","key":"10.1016\/j.schres.2026.06.012_bb0030","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1523\/JNEUROSCI.20-21-07871.2000","article-title":"Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus","volume":"20","author":"Awad","year":"2000","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0035","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.neuropharm.2007.12.009","article-title":"Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated","volume":"54","author":"Ayala","year":"2008","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0040","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s11011-018-0380-6","article-title":"GRM7 polymorphisms and risk of schizophrenia in Iranian population","volume":"34","author":"Azari","year":"2019","journal-title":"Metab. Brain Dis."},{"issue":"7","key":"10.1016\/j.schres.2026.06.012_bb0045","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1601-183X.2011.00720.x","article-title":"NR2B-deficient mice are more sensitive to the locomotor stimulant and depressant effects of ethanol","volume":"10","author":"Badanich","year":"2011","journal-title":"Genes Brain Behav."},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0050","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1001\/jamapsychiatry.2013.3469","article-title":"Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder","volume":"71","author":"Baker","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2026.06.012_bb0055","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1113\/jphysiol.1991.sp018901","article-title":"Agonists at metabotropic glutamate receptors presynaptically inhibit EPSCs in neonatal rat hippocampus","volume":"444","author":"Baskys","year":"1991","journal-title":"J. Physiol."},{"issue":"12","key":"10.1016\/j.schres.2026.06.012_bb0060","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s00213-016-4291-0","article-title":"Effects of acute memantine administration on matrics consensus cognitive battery performance in psychosis: testing an experimental medicine strategy","volume":"233","author":"Bhakta","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2026.06.012_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-9-71","article-title":"Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia","volume":"9","author":"Bitanihirwe","year":"2009","journal-title":"BMC Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2026.06.012_bb0070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00213-008-1289-2","article-title":"Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat","volume":"202","author":"Black","year":"2009","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pbb.2011.11.006","article-title":"The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling","volume":"101","author":"Bradley","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"15","key":"10.1016\/j.schres.2026.06.012_bb0080","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1523\/JNEUROSCI.16-15-04749.1996","article-title":"Compartmental localization of a metabotropic glutamate receptor (mGluR7): two different active sites at a retinal synapse","volume":"16","author":"Brandst\u00e4tter","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2026.06.012_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.108982","article-title":"The comparative effects of mGlu5 receptor positive allosteric modulators VU0409551 and VU0360172 on cognitive deficits and signalling in the sub-chronic PCP rat model for schizophrenia","volume":"208","author":"Brown","year":"2022","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.schres.2026.06.012_bb0090","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","article-title":"The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments","volume":"164","author":"Buchanan","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"March","key":"10.1016\/j.schres.2026.06.012_bb0095","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1100\/tsw.2002.146","article-title":"Altered short-term synaptic plasticity in mice lacking the metabotropic glutamate receptor mGlu7","volume":"2","author":"Bushell","year":"2002","journal-title":"Sci. World J."},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ph14030238","article-title":"Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences","volume":"14","author":"Carli","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0105","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1471-4159.2000.0750889.x","article-title":"Regulation of neurotransmitter release by metabotropic glutamate receptors","volume":"75","author":"Cartmell","year":"2000","journal-title":"J. Neurochem."},{"issue":"15","key":"10.1016\/j.schres.2026.06.012_bb0110","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00213-015-3920-3","article-title":"Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia","volume":"232","author":"Chaki","year":"2015","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb0115","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/0269881118822157","article-title":"Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials","volume":"33","author":"Chang","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41537-025-00604-2","article-title":"Symptomatic and cognitive effects of D-amino acid oxidase inhibitors in patients with schizophrenia: a meta-analysis of double-blind randomized controlled trials","volume":"11","author":"Chang","year":"2025","journal-title":"Schizophrenia"},{"key":"10.1016\/j.schres.2026.06.012_bb0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.schres.2020.06.019","article-title":"A polymorphism in the glutamate metabotropic receptor 7 is associated with cognitive deficits in the early phases of psychosis","volume":"249","author":"Chaumette","year":"2022","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.06.012_bb0130","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuroscience.2022.06.027","article-title":"Increasing the excitatory drive rescues excitatory\/inhibitory imbalance and mismatch negativity deficit caused by parvalbumin specific GluA1 deletion","volume":"496","author":"Chen-Engerer","year":"2022","journal-title":"Neuroscience"},{"issue":"July","key":"10.1016\/j.schres.2026.06.012_bb0135","article-title":"The mGlu7 receptor in schizophrenia - an update and future perspectives","volume":"218","author":"Cie\u015blik","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.schres.2026.06.012_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2018.00316","article-title":"Negative allosteric modulators of mGlu7 receptor as putative antipsychotic drugs","volume":"11","author":"Cie\u015blik","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"11","key":"10.1016\/j.schres.2026.06.012_bb0145","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.3390\/ijms20112781","article-title":"Reversal of MK-801-induced disruptions in social interactions and working memory with simultaneous administration of LY487379 and VU152100 in mice","volume":"20","author":"Cie\u015blik","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0150","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41380-025-03202-x","article-title":"Negative allosteric modulation of mGlu7 disrupts fear memory reconsolidation and glutamatergic signaling in rat and human brain tissue","volume":"31","author":"Ciobanu","year":"2026","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2026.06.012_bb0155","series-title":"Glycine Transporter-1 Inhibitors: A Patent Review (2011\u20132016)","author":"Cioffi","year":"2018"},{"issue":"6","key":"10.1016\/j.schres.2026.06.012_bb0160","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/sj.bjp.0705861","article-title":"Interactions between NMDA receptors and mGlu5 receptors expressed in HEK293 cells","volume":"142","author":"Collett","year":"2004","journal-title":"Br. J. Pharmacol."},{"issue":"September 27","key":"10.1016\/j.schres.2026.06.012_bb0165","article-title":"FDA approves drug with new mechanism of action for treatment of schizophrenia","author":"Commissioner, Office of the","year":"2024","journal-title":"FDA, FDA"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0170","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","article-title":"Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0175","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0306-4522(01)00591-7","article-title":"Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS","volume":"110","author":"Corti","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.schres.2026.06.012_bb0180","first-page":"1","article-title":"Novel drug treatments for schizophrenia","author":"Coyle","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0185","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41593-019-0552-7","article-title":"Prefrontal somatostatin interneurons encode fear memory","volume":"23","author":"Cummings","year":"2020","journal-title":"Nat. Neurosci."},{"issue":"12","key":"10.1016\/j.schres.2026.06.012_bb0190","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1002\/hbm.22955","article-title":"Insight and psychosis: functional and anatomical brain connectivity and self-reflection in schizophrenia","volume":"36","author":"\u0106ur\u010di\u0107-Blake","year":"2015","journal-title":"Hum. Brain Mapp."},{"issue":"9","key":"10.1016\/j.schres.2026.06.012_bb0195","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/cercor\/12.9.961","article-title":"Enrichment of mGluR7a in the presynaptic active zones of GABAergic and Non-GABAergic terminals on interneurons in the rat somatosensory cortex","volume":"12","author":"Dalezios","year":"2002","journal-title":"Cerebral Cortex (New York, N.Y.: 1991)"},{"issue":"9","key":"10.1016\/j.schres.2026.06.012_bb0200","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1176\/ajp.156.9.1328","article-title":"Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents","volume":"156","author":"Davidson","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0205","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbr.2004.05.016","article-title":"Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats","volume":"156","author":"de Lima","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.schres.2026.06.012_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175306","article-title":"Pro-cognitive effects of the GlyT1 inhibitor bitopertin in rodents","volume":"935","author":"Deiana","year":"2022","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.schres.2026.06.012_bb0215","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.20220676","article-title":"The nature of prefrontal cortical GABA neuron alterations in schizophrenia: markedly lower somatostatin and parvalbumin gene expression without missing neurons","volume":"180","author":"Dienel","year":"2023","journal-title":"Am. J. Psychiatry"},{"issue":"13","key":"10.1016\/j.schres.2026.06.012_bb0220","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1038\/npp.2013.170","article-title":"The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity","volume":"38","author":"Driesen","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"15","key":"10.1016\/j.schres.2026.06.012_bb0225","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.neuron.2023.05.002","article-title":"NMDA receptor functions in health and disease: old actor, new dimensions","volume":"111","author":"Dupuis","year":"2023","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0230","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2007.08.012","article-title":"Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats","volume":"186","author":"Enomoto","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0235","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.157.5.826","article-title":"Placebo-controlled trial of glycine added to clozapine in schizophrenia","volume":"157","author":"Evins","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamapsychiatry.2024.2890","article-title":"Antipsychotic drugs and cognitive function: a systematic review and network meta-analysis","volume":"82","author":"Feber","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2026.06.012_bb0245","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.biopsych.2017.11.033","article-title":"Thalamic control of cognition and social behavior via regulation of gamma-aminobutyric acidergic signaling and excitation\/inhibition balance in the medial prefrontal cortex","volume":"83","author":"Ferguson","year":"2018","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0250","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00441-006-0266-5","article-title":"Metabotropic glutamate receptors","volume":"326","author":"Ferraguti","year":"2006","journal-title":"Cell Tissue Res."},{"issue":"June","key":"10.1016\/j.schres.2026.06.012_bb0255","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-244X-12-64","article-title":"Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence","volume":"12","author":"Fioravanti","year":"2012","journal-title":"BMC Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2026.06.012_bb0260","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12654","article-title":"Phenotypic profiling of mGlu7 knockout mice reveals new implications for neurodevelopmental disorders","volume":"19","author":"Fisher","year":"2020","journal-title":"Genes Brain Behav."},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb0265","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143324","article-title":"A GRM7 mutation associated with developmental delay reduces mGlu7 expression and produces neurological phenotypes","volume":"6","author":"Fisher","year":"2021","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0270","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1471-4159.1996.66010161.x","article-title":"Characterization of the glutamate receptors mediating release of somatostatin from cultured hippocampal neurons","volume":"66","author":"Fontana","year":"1996","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0275","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.euroneuro.2013.10.017","article-title":"Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders","volume":"24","author":"Foussias","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"April","key":"10.1016\/j.schres.2026.06.012_bb0280","article-title":"GRM7 gene mutations and consequences for neurodevelopment","volume":"225","author":"Freitas","year":"2023","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"7","key":"10.1016\/j.schres.2026.06.012_bb0285","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1176\/appi.ajp.159.7.1183","article-title":"Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance","volume":"159","author":"Fuller","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0290","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neulet.2004.09.064","article-title":"Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression","volume":"373","author":"Gabernet","year":"2004","journal-title":"Neurosci. Lett."},{"issue":"32","key":"10.1016\/j.schres.2026.06.012_bb0295","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1523\/JNEUROSCI.0064-12.2012","article-title":"Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain","volume":"32","author":"Gleichman","year":"2012","journal-title":"J. Neurosci."},{"issue":"403","key":"10.1016\/j.schres.2026.06.012_bb0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai7459","article-title":"mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome","volume":"9","author":"Gogliotti","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0305","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/0269881120965937","article-title":"Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: a meta-analysis of randomised, placebo-controlled trials","volume":"35","author":"Goh","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0310","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1186\/s12888-022-04368-2","article-title":"Prevalence and correlates of cognitive impairment in schizophrenia: a cross-sectional study from a teaching hospital southern Sri Lanka","volume":"22","author":"Goonathilake","year":"2022","journal-title":"BMC Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2026.06.012_bb0315","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/mp.2015.91","article-title":"Sex differences in glutamate receptor gene expression in major depression and suicide","volume":"20","author":"Gray","year":"2015","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0320","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0325","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","article-title":"Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \u2018right stuff\u2019?","volume":"26","author":"Green","year":"2000","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0330","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/wps.20624","article-title":"Nonsocial and social cognition in schizophrenia: current evidence and future directions","volume":"18","author":"Green","year":"2019","journal-title":"World Psychiatry"},{"issue":"13","key":"10.1016\/j.schres.2026.06.012_bb0335","doi-asserted-by":"crossref","first-page":"10265","DOI":"10.1074\/jbc.M111.325175","article-title":"Regulation of N-methyl\u2011d-aspartic acid (NMDA) receptors by metabotropic glutamate receptor 7*","volume":"287","author":"Gu","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"41","key":"10.1016\/j.schres.2026.06.012_bb0340","doi-asserted-by":"crossref","first-page":"13614","DOI":"10.1523\/JNEUROSCI.1204-14.2014","article-title":"A\u03b2 selectively impairs mGluR7 modulation of NMDA signaling in basal forebrain cholinergic neurons: implication in Alzheimer\u2019s disease","volume":"34","author":"Gu","year":"2014","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb0345","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/pharmrev.120.000131","article-title":"Structure, function, and pharmacology of glutamate receptor ion channels","volume":"73","author":"Hansen","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.schres.2026.06.012_bb0350","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/s41386-023-01587-3","article-title":"Tryptophan challenge in individuals with schizophrenia and healthy controls: acute effects on circulating kynurenine and kynurenic acid, cognition and cerebral blood flow","volume":"48","author":"Hare","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"June","key":"10.1016\/j.schres.2026.06.012_bb0355","article-title":"Efficacy and safety of Iclepertin (BI 425809) with adjunctive computerized cognitive training in patients with schizophrenia","volume":"40","author":"Harvey","year":"2025","journal-title":"Schizophr. Res. Cogn."},{"issue":"10","key":"10.1016\/j.schres.2026.06.012_bb0360","article-title":"Cobenfy (xanomeline-trospium chloride): a new frontier in schizophrenia management","volume":"16","author":"Hasan","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.schres.2026.06.012_bb0365","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neuroscience.2020.08.021","article-title":"Organized resting-state functional dysconnectivity of the prefrontal cortex in patients with schizophrenia","volume":"446","author":"He","year":"2020","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0370","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0006-3223(03)00707-8","article-title":"High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia","volume":"55","author":"Heresco-Levy","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2026.06.012_bb0375","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1176\/ajp.155.9.1196","article-title":"Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life","volume":"155","author":"Ho","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.06.012_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.700822","article-title":"Partial mGlu5 negative allosteric modulator M-5MPEP demonstrates antidepressant-like effects on sleep without affecting cognition or quantitative EEG","volume":"15","author":"Holter","year":"2021","journal-title":"Front. Neurosci."},{"issue":"9","key":"10.1016\/j.schres.2026.06.012_bb0385","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1038\/s41380-025-02996-0","article-title":"17\u03b2-estradiol status alters NMDAR function and antipsychotic-like activity in female rats","volume":"30","author":"Holter","year":"2025","journal-title":"Mol. Psychiatry"},{"issue":"43","key":"10.1016\/j.schres.2026.06.012_bb0390","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0395","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2026.06.012_bb0400","doi-asserted-by":"crossref","unstructured":"Horan, William P., Lauren T. Catalano, and Michael F. Green. 2023. \u201cAn update on treatment of cognitive impairment associated with schizophrenia.\u201d In Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework, Edited by Deanna M. Barch and Jared W. Young. Springer International Publishing. doi:https:\/\/doi.org\/10.1007\/7854_2022_382.","DOI":"10.1007\/7854_2022_382"},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0405","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1176\/appi.ajp.20240076","article-title":"The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials","volume":"182","author":"Horan","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0410","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1472-8206.2012.01045.x","article-title":"Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice","volume":"27","author":"Horio","year":"2013","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0415","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.neuroscience.2009.08.004","article-title":"The role of rat dorsomedial prefrontal cortex in spatial working memory","volume":"164","author":"Horst","year":"2009","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.schres.2026.06.012_bb0420","article-title":"A prefrontal thalamocortical readout for conflict-related executive dysfunction in schizophrenia","volume":"5","author":"Huang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.schres.2026.06.012_bb0425","author":"Ingelheim, Boehringer (Boehringer Ingelheim)"},{"issue":"22","key":"10.1016\/j.schres.2026.06.012_bb0430","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1073\/pnas.0308455101","article-title":"NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex","volume":"101","author":"Jackson","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.schres.2026.06.012_bb0435","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/cn500153z","article-title":"Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7","volume":"5","author":"Jalan-Sakrikar","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"February","key":"10.1016\/j.schres.2026.06.012_bb0440","article-title":"GRM7-related disorder: five additional patients from three independent families and review of the literature","volume":"67","author":"Januel","year":"2024","journal-title":"Eur. J. Med. Genet."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0445","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-01951-w","article-title":"A large consanguineous family with a homozygous metabotropic glutamate receptor 7 (mGlu7) variant and developmental epileptic encephalopathy: effect on protein structure and ligand affinity","volume":"16","author":"Jdila","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"November","key":"10.1016\/j.schres.2026.06.012_bb0450","article-title":"Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients","volume":"8","author":"J\u00e9z\u00e9quel","year":"2017","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0455","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/cercor\/bhh168","article-title":"Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway","volume":"15","author":"Jodo","year":"2005","journal-title":"Cereb. Cortex"},{"issue":"6","key":"10.1016\/j.schres.2026.06.012_bb0460","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14458","article-title":"The economic burden of schizophrenia in the United States","volume":"83","author":"Kadakia","year":"2022","journal-title":"J. Clin. Psychiatry."},{"issue":"January","key":"10.1016\/j.schres.2026.06.012_bb0465","article-title":"Persistent challenges in the development of an mGlu7 PAM in vivo tool compound: the discovery of VU6046980","volume":"80","author":"Kalbfleisch","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.schres.2026.06.012_bb0470","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.schres.2017.02.027","article-title":"Improvement in mismatch negativity generation during D-serine treatment in schizophrenia: correlation with symptoms","volume":"191","author":"Kantrowitz","year":"2018","journal-title":"Schizophr. Res."},{"issue":"March","key":"10.1016\/j.schres.2026.06.012_bb0475","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.20250034","article-title":"Effect size deflation with increasing sample size in adjunctive trials for negative symptoms in schizophrenia: a meta-analysis and meta-regression across mechanisms of action","volume":"183","author":"Kantrowitz","year":"2026","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2026.06.012_bb0480","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/brain\/aww095","article-title":"Estimating changing contexts in schizophrenia","volume":"139","author":"Kaplan","year":"2016","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.schres.2026.06.012_bb0485","first-page":"956","article-title":"Functional connectivity of the striatum in schizophrenia and psychotic bipolar disorder","volume":"4","author":"Karcher","year":"2019","journal-title":"Biol. Psychiatry: Cognit. Neurosci. Neuroimaging"},{"key":"10.1016\/j.schres.2026.06.012_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109737","article-title":"Memantine: updating a rare success story in pro-cognitive therapeutics","volume":"244","author":"Karimi Tari","year":"2024","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.schres.2026.06.012_bb0495","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/ajp.2007.164.7.1061","article-title":"Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"Keefe","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0500","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","article-title":"The MATRICS consensus cognitive battery, part 2: co-norming and standardization","volume":"165","author":"Kern","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.06.012_bb0505","first-page":"1","article-title":"A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE study","author":"Khin","year":"2026","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.schres.2026.06.012_bb0510","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1038\/s41380-019-0401-9","article-title":"Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia","volume":"25","author":"Kindler","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0515","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.schres.2026.06.012_bb0520","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","volume":"78","author":"Kinon","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0525","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/(SICI)1096-9861(19980413)393:3<332::AID-CNE6>3.0.CO;2-2","article-title":"Immunohistochemical localization of metabotropic glutamate receptors, mGluR7a and mGluR7b, in the central nervous system of the adult rat and mouse: a light and electron microscopic study","volume":"393","author":"Kinoshita","year":"1998","journal-title":"J. Comp. Neurol."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0530","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0306-4522(95)00244-D","article-title":"Distribution of metabotropic glutamate receptor 7 messenger RNA in the developing and adult rat brain","volume":"69","author":"Kinzie","year":"1995","journal-title":"Neuroscience"},{"issue":"19","key":"10.1016\/j.schres.2026.06.012_bb0535","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1523\/JNEUROSCI.4543-14.2015","article-title":"Activation of metabotropic glutamate receptor 7 is required for induction of Long-term potentiation at SC-CA1 synapses in the hippocampus","volume":"35","author":"Klar","year":"2015","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.schres.2026.06.012_bb0540","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1176\/appi.ajp.162.6.1200","article-title":"Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia","volume":"162","author":"Kolluri","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0545","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/(SICI)1096-9861(19991213)415:2<266::AID-CNE9>3.0.CO;2-7","article-title":"Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia","volume":"415","author":"Kosinski","year":"1999","journal-title":"J. Comp. Neurol."},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb0550","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1037\/0021-843X.109.4.743","article-title":"The paradox of normal neuropsychological function in schizophrenia","volume":"109","author":"Kremen","year":"2000","journal-title":"J. Abnorm. Psychol."},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0555","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0560","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00221-022-06530-4","article-title":"Sarcosine (Glycine transporter inhibitor) attenuates behavioural and biochemical changes induced by ketamine, in the rat model of schizophrenia","volume":"241","author":"Kumar","year":"2023","journal-title":"Exp. Brain Res."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0565","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb0570","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0575","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally","year":"2015","journal-title":"Br. Med. Bull."},{"issue":"September","key":"10.1016\/j.schres.2026.06.012_bb0580","article-title":"Layer III pyramidal cells in the prefrontal cortex reveal morphological changes in subjects with depression, schizophrenia, and suicide","volume":"12","author":"Larsen","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0585","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.97","article-title":"Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813","volume":"3","author":"Lavreysen","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"issue":"15","key":"10.1016\/j.schres.2026.06.012_bb0590","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1021\/acschemneuro.5c00174","article-title":"Profiling the impact of mGlu7\/Elfn1 protein interactions on the pharmacology of mGlu7 allosteric modulators","volume":"16","author":"Lei","year":"2025","journal-title":"ACS Chem. Neurosci."},{"issue":"10","key":"10.1016\/j.schres.2026.06.012_bb0595","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1176\/appi.ajp.20240738","article-title":"Antipsychotic drugs: a concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application","volume":"181","author":"Leucht","year":"2024","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0600","article-title":"Hippocampal-prefrontal circuit and disrupted functional connectivity in psychiatric and neurodegenerative disorders","volume":"2015","author":"Li","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0605","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.euroneuro.2015.05.004","article-title":"Significant association of GRM7 and GRM8 genes with schizophrenia and major depressive disorder in the Han Chinese population","volume":"26","author":"Li","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"29","key":"10.1016\/j.schres.2026.06.012_bb0610","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine targeting drugs for the treatment of schizophrenia: past, present and future","volume":"16","author":"Li","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"issue":"March","key":"10.1016\/j.schres.2026.06.012_bb0615","article-title":"Repeated blockade of NMDA receptors during adolescence impairs reversal learning and disrupts GABAergic interneurons in rat medial prefrontal cortex","volume":"9","author":"Li","year":"2016","journal-title":"Front. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-0763-4","article-title":"Variants of GRM7 as risk factor and response to antipsychotic therapy in schizophrenia","volume":"10","author":"Liang","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0625","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/schbul\/sbq086","article-title":"Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia","volume":"38","author":"Linderholm","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2026.06.012_bb0630","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2016.02.001","article-title":"AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study","volume":"172","author":"Litman","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.06.012_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105045","article-title":"Differential depletion of GluN2A induces heterogeneous schizophrenia-related phenotypes in mice","volume":"102","author":"Lu","year":"2024","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0640","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archneurpsyc.1959.02340150095011","article-title":"Study of a new schizophrenomimetic drug; Sernyl","volume":"81","author":"Luby","year":"1959","journal-title":"A.M A. Arch. Neurol. Psychiatry."},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0645","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1124\/pharmrev.121.000540","article-title":"Allosteric modulators of metabotropic glutamate receptors as novel therapeutics for neuropsychiatric disease","volume":"74","author":"Luessen","year":"2022","journal-title":"Pharmacol. Rev."},{"issue":"10","key":"10.1016\/j.schres.2026.06.012_bb0650","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/s41386-022-01350-0","article-title":"mGlu1-mediated restoration of prefrontal cortex inhibitory signaling reverses social and cognitive deficits in an NMDA hypofunction model in mice","volume":"47","author":"Luessen","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.schres.2026.06.012_bb0655","doi-asserted-by":"crossref","first-page":"697","DOI":"10.5607\/en.2019.28.6.697","article-title":"Recapitulation of neuropsychiatric behavioral features in mice using acute low-dose MK-801 administration","volume":"28","author":"Mabunga","year":"2019","journal-title":"Exp. Neurobiol."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0660","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0169-328X(96)00110-6","article-title":"Human metabotropic glutamate receptor type 7: molecular cloning and mRNA distribution in the CNS","volume":"40","author":"Makoff","year":"1996","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109950","article-title":"mGlu1 potentiation enhances prelimbic somatostatin interneuron activity to rescue schizophrenia-like physiological and cognitive deficits","volume":"37","author":"Maksymetz","year":"2021","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0670","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/acn3.51003","article-title":"Biallelic GRM7 variants cause epilepsy, microcephaly, and cerebral atrophy","volume":"7","author":"Marafi","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0675","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1460-9568.2007.05660.x","article-title":"mGluR7 inhibits glutamate release through a PKC-independent decrease in the activity of P\/Q-type Ca2+ channels and by diminishing cAMP in hippocampal nerve terminals","volume":"26","author":"Mart\u00edn","year":"2007","journal-title":"Eur. J. Neurosci."},{"issue":"23","key":"10.1016\/j.schres.2026.06.012_bb0680","doi-asserted-by":"crossref","first-page":"17907","DOI":"10.1074\/jbc.M109.080838","article-title":"The metabotropic glutamate receptor mGlu7 activates phospholipase C, translocates Munc-13-1 protein, and potentiates glutamate release at cerebrocortical nerve terminals*","volume":"285","author":"Mart\u00edn","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"February","key":"10.1016\/j.schres.2026.06.012_bb0685","article-title":"Early treatment with JNJ-46356479, a mGluR2 modulator, improves behavioral and neuropathological deficits in a postnatal ketamine mouse model of schizophrenia","volume":"158","author":"Mart\u00ednez-Pinte\u00f1o","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0690","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1523\/JNEUROSCI.19-03-00955.1999","article-title":"Metabotropic glutamate receptor subtype 7 ablation causes deficit in fear response and conditioned taste aversion","volume":"19","author":"Masugi","year":"1999","journal-title":"J. Neurosci."},{"issue":"5965","key":"10.1016\/j.schres.2026.06.012_bb0695","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/309261a0","article-title":"Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones","volume":"309","author":"Mayer","year":"1984","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0700","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2026.06.012_bb0705","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0006-3223(99)00255-3","article-title":"Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions","volume":"46","author":"Meltzer","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2026.06.012_bb0710","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb0715","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyaf015","article-title":"From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1\/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials","volume":"28","author":"Meyer","year":"2025","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0720","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0896-6273(94)90210-0","article-title":"Developmental and regional expression in the rat brain and functional properties of four NMDA receptors","volume":"12","author":"Monyer","year":"1994","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.schres.2026.06.012_bb0725","first-page":"1575","article-title":"Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder","volume":"18","author":"Morris","year":"2008","journal-title":"Cerebral Cortex (New York, N.Y.\u202f: 1991)"},{"issue":"6","key":"10.1016\/j.schres.2026.06.012_bb0730","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1124\/mol.106.032961","article-title":"Involvement of a dysfunctional dopamine-D1\/N-methyl\u2011d-aspartate-NR1 and Ca2+\/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine","volume":"71","author":"Mouri","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.schres.2026.06.012_bb0735","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-016-0003-3","article-title":"Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia","volume":"3","author":"Nakazawa","year":"2017","journal-title":"NPJ Schizophr."},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0740","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/schbul\/sbt124","article-title":"Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia","volume":"40","author":"Natsubori","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0745","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0893-133X(98)00067-0","article-title":"Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis","volume":"20","author":"Newcomer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2026.06.012_bb0750","doi-asserted-by":"crossref","DOI":"10.1080\/03007995.2018.1498779","article-title":"Changes in metabolic parameters and body weight in Brexpiprazole-treated patients with acute schizophrenia: Pooled analyses of Phase 3 clinical studies","author":"Newcomer","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"7","key":"10.1016\/j.schres.2026.06.012_bb0755","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1528-1167.2011.03082.x","article-title":"Metabotropic glutamate receptors in the thalamocortical network: strategic targets for the treatment of absence epilepsy","volume":"52","author":"Ngomba","year":"2011","journal-title":"Epilepsia"},{"issue":"February","key":"10.1016\/j.schres.2026.06.012_bb0760","article-title":"Targeting mGlu receptors for optimization of antipsychotic activity and disease-modifying effect in schizophrenia","volume":"10","author":"Nicoletti","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0765","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.110.170506","article-title":"Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats","volume":"335","author":"Nikiforuk","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.schres.2026.06.012_bb0770","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.764","article-title":"Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in na\u00efve and MK-801-treated mice","volume":"7","author":"Ning","year":"2017","journal-title":"Brain Behav."},{"key":"10.1016\/j.schres.2026.06.012_bb0775","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0780","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/YPG.0000000000000161","article-title":"Association study of GRM7 polymorphisms with major depressive disorder in the Chinese Han population","volume":"27","author":"Niu","year":"2017","journal-title":"Psychiatr. Genet."},{"issue":"11","key":"10.1016\/j.schres.2026.06.012_bb0785","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/aur.1640","article-title":"Glutamate receptor, metabotropic 7 (GRM7) gene variations and susceptibility to autism: a case-control study","volume":"9","author":"Noroozi","year":"2016","journal-title":"Autism Res."},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0790","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS consensus cognitive battery, Part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.06.012_bb0795","doi-asserted-by":"crossref","unstructured":"Nuechterlein, Keith H., Michael F. Green, and Robert S. Kern. 2023. The MATRICS consensus cognitive battery: an update In Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework, Edited by Deanna M. Barch and Jared W. Young. Springer International Publishing. doi:https:\/\/doi.org\/10.1007\/7854_2022_395.","DOI":"10.1007\/7854_2022_395"},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb0800","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cne.903600402","article-title":"Distributions of the mRNAs for L-2-Amino-4-phosphonobutyrate-sensitive metabotropic glutamate receptors, mGluR4 and mGluR7, in the rat brain","volume":"360","author":"Ohishi","year":"1995","journal-title":"J. Comp. Neurol."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0805","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41398-024-03194-2","article-title":"Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2\/3 (mGluR2\/3) in animal models of schizophrenia","volume":"15","author":"Olivares-Berjaga","year":"2025","journal-title":"Transl. Psychiatry"},{"issue":"18","key":"10.1016\/j.schres.2026.06.012_bb0810","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810624","article-title":"New atypical antipsychotics in the treatment of schizophrenia and depression","volume":"23","author":"Orzelska-G\u00f3rka","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb0815","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.neuropharm.2008.06.033","article-title":"Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents","volume":"55","author":"Pa\u0142ucha-Poniewiera","year":"2008","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.schres.2026.06.012_bb0820","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn3504","article-title":"NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease","volume":"14","author":"Paoletti","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0825","doi-asserted-by":"crossref","DOI":"10.1186\/1744-9081-9-1","article-title":"Association between the GRM7 Rs3792452 polymorphism and attention deficit hyperacitiveity disorder in a Korean sample","volume":"9","author":"Park","year":"2013","journal-title":"Behav. Brain Funct."},{"key":"10.1016\/j.schres.2026.06.012_bb0830","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuropharm.2012.12.003","article-title":"Mechanism based neurotoxicity of mGlu5 positive allosteric modulators \u2013 development challenges for a promising novel antipsychotic target","volume":"82","author":"Parmentier-Batteur","year":"2014","journal-title":"Neuropharmacology"},{"issue":"February","key":"10.1016\/j.schres.2026.06.012_bb0835","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.schres.2022.12.047","article-title":"The role of optogenetic stimulations of Parvalbumin-positive interneurons in the prefrontal cortex and the ventral hippocampus on an acute MK-801 model of schizophrenia-like cognitive inflexibility","volume":"252","author":"Patrono","year":"2023","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.schres.2026.06.012_bb0840","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am. J. Psychiatry"},{"issue":"October","key":"10.1016\/j.schres.2026.06.012_bb0845","article-title":"Directly and indirectly targeting the glycine modulatory site to modulate NMDA receptor function to address unmet medical needs of patients with schizophrenia","volume":"12","author":"Pei","year":"2021","journal-title":"Front. Psychiatry."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-019-0603-6","article-title":"Region specific knockdown of parvalbumin or somatostatin produces neuronal and behavioral deficits consistent with those observed in schizophrenia","volume":"9","author":"Perez","year":"2019","journal-title":"Transl. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2026.06.012_bb0855","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/nn.3446","article-title":"Inhibition of inhibition in visual cortex: the logic of connections between molecularly distinct interneurons","volume":"16","author":"Pfeffer","year":"2013","journal-title":"Nat. Neurosci."},{"issue":"10","key":"10.1016\/j.schres.2026.06.012_bb0860","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1111\/j.1460-9568.2012.08064.x","article-title":"Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood","volume":"35","author":"Pocivavsek","year":"2012","journal-title":"Eur. J. Neurosci."},{"issue":"24","key":"10.1016\/j.schres.2026.06.012_bb0865","doi-asserted-by":"crossref","first-page":"22291","DOI":"10.1021\/acs.jmedchem.4c02554","article-title":"Discovery of VU6024578\/BI02982816: an mGlu1 positive allosteric modulator with efficacy in preclinical antipsychotic and cognition models","volume":"67","author":"Reed","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.schres.2026.06.012_bb0870","doi-asserted-by":"crossref","DOI":"10.1080\/13803390500360372","article-title":"Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders","author":"Reichenberg","year":"2006","journal-title":"J. Clin. Exp. Neuropsychol."},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb0875","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/1092","article-title":"Target-cell-specific facilitation and depression in neocortical circuits","volume":"1","author":"Reyes","year":"1998","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb0880","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.neuron.2015.03.063","article-title":"Biased mGlu5-positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents","volume":"86","author":"Rook","year":"2015","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0885","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.121.001071","article-title":"Effects of the glycine transporter-1 inhibitor Iclepertin (BI 425809) on sensory processing, neural network function, and cognition in animal models related to schizophrenia","volume":"382","author":"Rosenbrock","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.schres.2026.06.012_bb0890","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","article-title":"Development of the novel GlyT1 inhibitor, Iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia","volume":"273","author":"Rosenbrock","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"22","key":"10.1016\/j.schres.2026.06.012_bb0895","doi-asserted-by":"crossref","first-page":"8734","DOI":"10.1523\/JNEUROSCI.21-22-08734.2001","article-title":"Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7","volume":"21","author":"Sansig","year":"2001","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0900","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0026-895X(25)10006-0","article-title":"Cloning and expression of a new member of the L-2-amino-4-phosphonobutyric acid-sensitive class of metabotropic glutamate receptors","volume":"45","author":"Saugstad","year":"1994","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0905","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can. J. Psychiatr."},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0910","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.biopsych.2023.01.015","article-title":"Dose dependent augmentation of neuroplasticity-based auditory learning in schizophrenia: a double-blind, placebo-controlled, randomized, target engagement clinical trial of the N-methyl-D-aspartate-type glutamate receptor (NMDAR) agonist D-serine","volume":"94","author":"Sehatpour","year":"2023","journal-title":"Biol. Psychiatry"},{"issue":"6582","key":"10.1016\/j.schres.2026.06.012_bb0915","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/381523a0","article-title":"Target-cell-specific concentration of a metabotropic glutamate receptor in the presynaptic active zone","volume":"381","author":"Shigemoto","year":"1996","journal-title":"Nature"},{"issue":"January","key":"10.1016\/j.schres.2026.06.012_bb0920","article-title":"Hippocampal-prefrontal interactions in cognition, behavior and psychiatric disease","volume":"9","author":"Sigurdsson","year":"2016","journal-title":"Front. Syst. Neurosci."},{"issue":"May","key":"10.1016\/j.schres.2026.06.012_bb0925","article-title":"Inhibition of astrocytic glycine transporter-1: friend or foe for ameliorating NMDA receptor hypofunction?","volume":"18","author":"Singer","year":"2024","journal-title":"Front. Cell. Neurosci."},{"issue":"7906","key":"10.1016\/j.schres.2026.06.012_bb0930","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","article-title":"Rare coding variants in ten genes confer substantial risk for schizophrenia","volume":"604","author":"Singh","year":"2022","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.schres.2026.06.012_bb0935","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/bph.12254","article-title":"The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents","volume":"169","author":"S\u0142awi\u0144ska","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0940","doi-asserted-by":"crossref","first-page":"2","DOI":"10.9758\/cpn.24.1253","article-title":"Xanomeline-trospium (CobenfyTM) for schizophrenia: a review of the literature","volume":"23","author":"Smith","year":"2025","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"9","key":"10.1016\/j.schres.2026.06.012_bb0945","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41380-019-0426-0","article-title":"Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders","volume":"24","author":"Sohal","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2026.06.012_bb0950","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the global burden of disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0955","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s12276-021-00580-4","article-title":"The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders","volume":"53","author":"Song","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"23","key":"10.1016\/j.schres.2026.06.012_bb0960","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1523\/JNEUROSCI.2276-18.2019","article-title":"Elfn1-Induced constitutive activation of mGluR7 determines frequency-dependent recruitment of Somatostatin interneurons","volume":"39","author":"Stachniak","year":"2019","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb0965","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2010.01.028","article-title":"Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade","volume":"639","author":"Stefani","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.schres.2026.06.012_bb0970","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/molecules23082087","article-title":"Current concepts and treatments of schizophrenia","volume":"23","author":"St\u0119pnicki","year":"2018","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb0975","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bcp.13466","article-title":"Results and evaluation of a first-in-human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods","volume":"84","author":"Sturm","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb0980","article-title":"Anti-N-methyl-D-aspartate receptor encephalitis: a detailed review of the different psychiatric presentations and red flags to look for in suspected cases","volume":"13","author":"Subeh","year":"2021","journal-title":"Cureus"},{"issue":"2\u20133","key":"10.1016\/j.schres.2026.06.012_bb0985","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2012.03.011","article-title":"Multimodal analyses identify linked functional and white matter abnormalities within the working memory network in schizophrenia","volume":"138","author":"Sugranyes","year":"2012","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb0990","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/npp.2015.162","article-title":"Memantine effects on sensorimotor gating and mismatch negativity in patients with chronic psychosis","volume":"41","author":"Swerdlow","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"14","key":"10.1016\/j.schres.2026.06.012_bb0995","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00213-017-4613-x","article-title":"Effect of clozapine on ketamine-induced deficits in attentional set shift task in mice","volume":"234","author":"Szlachta","year":"2017","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb1000","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1471-4159.1989.tb07406.x","article-title":"Actions of excitatory amino acids on somatostatin release from cortical neurons in primary cultures","volume":"53","author":"Tapia-Arancibia","year":"1989","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.schres.2026.06.012_bb1005","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/schbul\/sbaa074","article-title":"The trace kynurenine, cinnabarinic acid, displays potent antipsychotic-like activity in mice and its levels are reduced in the prefrontal cortex of individuals affected by schizophrenia","volume":"46","author":"Ulivieri","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb1010","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/schbul\/sbaa184","article-title":"A role for somatostatin-positive interneurons in neuro-oscillatory and information processing deficits in schizophrenia","volume":"47","author":"Van Derveer","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"November","key":"10.1016\/j.schres.2026.06.012_bb1015","article-title":"Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: what is the evidence?","volume":"13","author":"Vasiliu","year":"2022","journal-title":"Front. Psychiatry"},{"issue":"19","key":"10.1016\/j.schres.2026.06.012_bb1020","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1016\/j.neuron.2024.06.028","article-title":"Ketamine alleviates NMDA receptor hypofunction through synaptic trapping","volume":"112","author":"Vill\u00e9ga","year":"2024","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb1025","doi-asserted-by":"crossref","DOI":"10.1002\/jnr.25257","article-title":"Understanding the role of the NMDA receptor subunit, GluN2D, in mediating NMDA receptor antagonist-induced behavioral disruptions in male and female mice","volume":"102","author":"Vinnakota","year":"2024","journal-title":"J. Neurosci. Res."},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110659","article-title":"Prefrontal pyramidal neurons are critical for all phases of working memory","volume":"39","author":"Vogel","year":"2022","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.schres.2026.06.012_bb1035","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.neuron.2008.09.039","article-title":"Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks","volume":"60","author":"von Engelhardt","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.schres.2026.06.012_bb1040","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.2147\/DDDT.S240859","article-title":"Brexpiprazole for the treatment of schizophrenia in adults: an overview of its clinical efficacy and safety and a psychiatrist\u2019s perspective","volume":"14","author":"Watanabe","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"June","key":"10.1016\/j.schres.2026.06.012_bb1045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainres.2010.03.078","article-title":"GABAergic dysfunction in mGlu7 receptor-deficient mice as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and increased Reelin proteins in the Hippocampus","volume":"1334","author":"Wiero\u0144ska","year":"2010","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.schres.2026.06.012_bb1050","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00213-011-2502-2","article-title":"Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia","volume":"220","author":"Wiero\u0144ska","year":"2012","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2026.06.012_bb1055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-014-3657-4","article-title":"The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies","volume":"232","author":"Wiero\u0144ska","year":"2015","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2026.06.012_bb1060","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s41380-021-01320-w","article-title":"Effect of mGluR2 positive allosteric modulation on frontostriatal working memory activation in schizophrenia","volume":"27","author":"Wolf","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"October","key":"10.1016\/j.schres.2026.06.012_bb1065","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1176\/appi.ajp.2012.12010056","article-title":"Thalamocortical dysconnectivity in schizophrenia","volume":"169","author":"Woodward","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2026.06.012_bb1070","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1017\/S146114570900042X","article-title":"Dizocilpine (MK-801) induces distinct changes of N-methyl\u2011d-aspartic acid receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortex","volume":"12","author":"Xi","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"July","key":"10.1016\/j.schres.2026.06.012_bb1075","article-title":"Prefrontal GABAergic interneurons gate Long-range afferents to regulate prefrontal cortex-associated complex behaviors","volume":"15","author":"Yang","year":"2021","journal-title":"Front. Neural Circuits"},{"issue":"12","key":"10.1016\/j.schres.2026.06.012_bb1080","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1523\/JNEUROSCI.5120-05.2006","article-title":"Disruption of Glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile","volume":"26","author":"Yee","year":"2006","journal-title":"J. Neurosci."},{"issue":"7363","key":"10.1016\/j.schres.2026.06.012_bb1085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nature10360","article-title":"Neocortical excitation\/inhibition balance in information processing and social dysfunction","volume":"477","author":"Yizhar","year":"2011","journal-title":"Nature"},{"issue":"January","key":"10.1016\/j.schres.2026.06.012_bb1090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41398-017-0061-y","article-title":"Rare loss of function mutations in N-methyl\u2011d-aspartate glutamate receptors and their contributions to schizophrenia susceptibility","volume":"8","author":"Yu","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.schres.2026.06.012_bb1095","series-title":"Glial Amino Acid Transporters","article-title":"Glycine transporters and its coupling with NMDA receptors","author":"Zafra","year":"2017"},{"key":"10.1016\/j.schres.2026.06.012_bb1100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.schres.2025.06.002","article-title":"Aberrant prefrontal-hippocampal connectivity of cross-modal associative memory impairment in schizophrenia","volume":"282","author":"Zhai","year":"2025","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.06.012_bb1105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jpsychires.2018.09.020","article-title":"Voltage-gated calcium channel activity and complex related genes and schizophrenia: a systematic investigation based on Han Chinese population","volume":"106","author":"Zhang","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"January","key":"10.1016\/j.schres.2026.06.012_bb1110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpsychires.2020.09.035","article-title":"Association between the group III metabotropic glutamate receptor gene polymorphisms and attention-deficit\/hyperactivity disorder and functional exploration of risk loci","volume":"132","author":"Zhang","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2026.06.012_bb1115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jpsychires.2018.06.005","article-title":"Short-term efficacy and tolerability of Lurasidone in the treatment of acute schizophrenia: a meta-analysis of randomized controlled trials","volume":"103","author":"Zheng","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"July","key":"10.1016\/j.schres.2026.06.012_bb1120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.schres.2019.05.019","article-title":"Adjunctive Memantine for major mental disorders: a systematic review and meta-analysis of randomized double-blind controlled trials","volume":"209","author":"Zheng","year":"2019","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2026.06.012_bb1125","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1042\/BST20230122","article-title":"Structural insights into NMDA receptor pharmacology","volume":"51","author":"Zhou","year":"2023","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.schres.2026.06.012_bb1130","first-page":"728","article-title":"A multicenter, add-on randomized controlled trial of low-dose d-Serine for negative and cognitive symptoms of schizophrenia Schizophrenia\/Schizoaffective Disorders","volume":"73","author":"Zimmerman","year":"2012","journal-title":"Psychiatrist.Com"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426001957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426001957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:08:56Z","timestamp":1793045336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426001957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":226,"alternative-id":["S0920996426001957"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.06.012","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}